<unk>  (trade name Vyzulta) is an ophthalmic drug approved in the United States in 2017 for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. It targets the trabecular meshwork directly.
Latanoprostene bunod
Travoprost/timolol
Netarsudil/latanoprost
Latanoprost/timolol
Bimatoprost/timolol
Carboprost
Travoprost
Iloprost